IRLAB held its first Capital Markets Day on March 22, 2022. During the day, IRLAB’s operations and lead programs were presented.

Steven Glyman, SVP and Head of Neuroscience at Ipsen talked about the cooperation with IRLAB and what they saw that made them inlicense mesdopetam.

Professor Karl Kieburtz, a world leading authority within treatment of Parkinson’s disease, motor complications and drug development talked about PD-LIDs, PD-P and the benefits mesdopetam can offer many patients.

Professor Bastiaan Bloem, one of the world’s leading experts on impaired balance and falls in Parkinson’s disease talked about the huge unmet need for new treatments and how pirepemat could make big difference for many patients.